Antibody-dependent cell-mediated cytotoxicity (ADCC) is a significant mechanism of action of antibodies that direct the elimination of pathogenic or virus-infected cells by cell-mediated immune system components. The conventional ADCC bioassay uses the released labeled radioactivities or enzymes as a readout to quantify the lysis of target cells by NK cells. However, high costs and other obstacles hinder the development of conventional ADCC bioassay. At present, the conventional method is being increasingly replaced by a cell-based reporter gene assay, which provides a high-sensitive and high-throughput screening manner for drug discovery.
Fig.1 A natural killer (NK) cell targets tumor cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC).1
To overcome these obstacles, Creative Biolabs successfully developed a cost-effective Mouse ADCC reporter assay. On the basis of conventional ADCC assay, we introduce the reporter gene into the effector cell and co-culture it with the target cell, subsequent to the treatment of candidate antibody drugs, we measure the luminescence signal to reflect the potency and efficacy of candidate antibody drugs. At Creative Biolabs, we will devise the most suitable solution in accordance with your specifications and make every effort to deliver optimal results.
Fig.2 Illustration of our mouse ADCC reporter assay.
Off-the-shelf functional and expression cell lines are available for free, significantly lowering R&D expenses.
Our assay takes no pre-lab time and may provide results in as little as a week.
Our expert team closely monitors the progress of the project and offers comprehensive technical support.
We provide a one-stop service from method development to assay services according to global customers' diverse needs.
Case 1: This study developed a robust reporter gene assay to investigate the ADCC activity of anti-MERS antibodies by combining 293T/MERS cells expressing MERS-CoV spike protein (MERS-S) as target cells with modified Jurkat/NFAT-luc/FcRIIIa cells expressing FcRIIIA and NFAT reporter gene. They utilized the ICH-Q2 methodology to optimize the studies and evaluate the quality of this assay. Furthermore, the research found that fucosylated anti-MERS antibodies exhibited better ADCC activity than non-fucosylated anti-MERS antibodies. This technique of assessing ADCC offers a unique approach to evaluating anti-MERS antibody bioactivity and boosting ADCC activity by modifying N-glycosylation of the Fc region.
Fig.3 FcγRIIIa effector cells utilized in an ADCC reporter assay.2
Q1: How to evaluate ADCC?
A1: On the basis of conventional ADCC assay, we introduce the reporter gene into the effector cell and co-culture it with the target cell, subsequent to the treatment of candidate antibody drugs, we measure the luminescence signal to reflect the potency and efficacy of antibody drugs.
Creative Biolabs is committed to improving our technology and services in order to better assist drug development efforts. Whether your objective is to demonstrate that your molecule does not induce cytotoxicity or require cytotoxicity, we will diligently develop an optimal solution that adheres to your specifications. We are committed to delivering results that surpass your expectations. If you have any questions or would like more details about our mouse ADCC reporter assay, please don't hesitate to get in touch with us.
References
For Research Use Only.
